Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369340 | 0.80 | TAAR1 (0.44) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL989251 | 0.78 | IDO1 (0.42) | TAAR1MAOACYP2A6TP53 | |
| SCHEMBL18221776 | 0.76 | TAAR1 (0.41) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2018585 | 0.76 | TSHR (0.42) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28443883 | 0.75 | TAAR1 (0.40) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28454966 | 0.75 | SIGMAR1 (0.42) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Lithium Ion SCHEMBL752620 | 0.73 | TAAR1 (0.39) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL751758 | 0.73 | TAAR1 (0.39) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Potassium Ion SCHEMBL754107 | 0.73 | TAAR1 (0.39) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28630832 | 0.72 | SIGMAR1 (0.38) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | TAAR1 107/4885SIGMAR1 227/4885SLC6A2 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.